Potent Antifolates as New Therapeutics for MRSA

有效的抗叶酸剂作为 MRSA 的新疗法

基本信息

  • 批准号:
    8089567
  • 负责人:
  • 金额:
    $ 76.37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-08-01 至 2013-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This Phase II STTR proposal describes a collaborative effort between researchers in the Department of Pharmaceutical Sciences at the University of Connecticut and Promiliad Biopharma to develop efficacious antibiotics targeting both methicillin-resistant strains of Staphylococcus aureus (MRSA) and Streptococcus pyogenes. We have recently completed a Phase I STTR grant that was focused on developing agents against the parasitic protozoan Cryptosporidium hominis by targeting the essential enzyme dihydrofolate reductase (DHFR). Through this work we developed the most potent and selective inhibitors of this enzyme reported to date and showed efficacy against the cultured parasite. In parallel with these efforts targeting Cryptosporidium, we examined the generality of this compound class to inhibit DHFR from other pathogenic organisms and found that this scaffold can be customized to potently target a wide range of pathogenic DHFR enzymes, including that from MRSA and Streptococcus pyogenes. We intend to capitalize on the high-profile nature of these organisms by switching the focus of our first proof-of-concept antibiotic. We have shown that the compounds effectively inhibit the growth of various phenotypes of MRSA and Streptococcus pyogenes. Moreover, we have determined several high-resolution crystal structures of the pathogenic MRSA enzyme in complex with representative inhibitors, placing us in a strong position to further develop these new antibiotics. The efforts to develop an efficacious candidate compound will evolve through three specific aims. In the first Aim, we will complete an initial analog series and select two lead compounds to move forward into animal studies in the second specific aim. These studies will determine key pharmacokinetic parameters (bioavailability, half-life) for our compounds as well as determine efficacy in an animal model of infection. In the third specific aim, we will explore new, structure-based designs to enhance the selectivity of our compounds for the pathogenic forms of DHFR over the human homolog. Completion of these studies will position us to attract outside investors and partners to progress our compounds for an IND application. PUBLIC HEALTH RELEVANCE: Despite decades of work on the discovery of antibiotics, the continued emergence of resistance organisms threatens to render many of our best antibiotics obsolete. We are working to develop new agents against that function as effective monotherapies against the methicillin-resistant strain of Staphylococcus aureus (MRSA) and Streptococcus pyogenes. Specifically we are targeting the essential enzyme dihydrofolate reductase (DHFR) that is required by the bacteria to synthesize key components needed to replicate its genetic material.
描述(由申请人提供):本II期STTR提案描述了康涅狄格大学药学系研究人员与Promiliad Biologyma合作开发针对金黄色葡萄球菌(MRSA)和化脓性链球菌耐甲氧西林菌株的有效抗生素。我们最近完成了一期STTR拨款,重点是通过靶向必需酶二氢叶酸还原酶(DHFR)开发针对寄生原生动物人隐孢子虫的药物。通过这项工作,我们开发了迄今为止报道的这种酶的最有效和选择性的抑制剂,并显示出对培养的寄生虫的功效。在这些针对隐孢子虫的努力的同时,我们检查了这种化合物类抑制来自其他病原生物的DHFR的一般性,并发现这种支架可以定制为有效地靶向广泛的病原DHFR酶,包括来自MRSA和化脓性链球菌的DHFR酶。我们打算通过改变我们第一个概念验证抗生素的焦点来利用这些生物体的高调性质。我们已经表明,化合物有效地抑制MRSA和化脓性链球菌的各种表型的生长。此外,我们已经确定了致病性MRSA酶与代表性抑制剂复合的几种高分辨率晶体结构,使我们在进一步开发这些新抗生素方面处于有利地位。开发有效候选化合物的努力将通过三个具体目标进行。在第一个目标中,我们将完成一个初始的类似物系列,并选择两个先导化合物进入第二个特定目标的动物研究。这些研究将确定我们的化合物的关键药代动力学参数(生物利用度,半衰期),并确定在感染动物模型中的疗效。在第三个具体目标中,我们将探索新的基于结构的设计,以提高我们的化合物对DHFR致病形式的选择性。这些研究的完成将使我们能够吸引外部投资者和合作伙伴来推进我们的化合物的IND申请。 公共卫生相关性:尽管在抗生素的发现上进行了数十年的工作,但耐药微生物的持续出现有可能使我们许多最好的抗生素过时。我们正在努力开发新的药物,作为有效的单一疗法,对耐甲氧西林金黄色葡萄球菌(MRSA)和化脓性链球菌菌株。具体来说,我们针对的是细菌合成复制其遗传物质所需的关键成分所需的必需酶二氢叶酸还原酶(DHFR)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dennis L. Wright其他文献

Dennis L. Wright的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dennis L. Wright', 18)}}的其他基金

Therapeutic Agents Targeting Cryptococcal Infections
针对隐球菌感染的治疗药物
  • 批准号:
    10697960
  • 财政年份:
    2023
  • 资助金额:
    $ 76.37万
  • 项目类别:
New Agents for the Treatment on Mycobacteria Avium Infections
治疗鸟分枝杆菌感染的新药
  • 批准号:
    10597233
  • 财政年份:
    2022
  • 资助金额:
    $ 76.37万
  • 项目类别:
New Agents for the Treatment on Mycobacteria Avium Infections
治疗鸟分枝杆菌感染的新药
  • 批准号:
    10482476
  • 财政年份:
    2022
  • 资助金额:
    $ 76.37万
  • 项目类别:
Development of Broad Spectrum Antifungal Agents
广谱抗真菌药物的开发
  • 批准号:
    9909111
  • 财政年份:
    2020
  • 资助金额:
    $ 76.37万
  • 项目类别:
Antimetabolites for Acute Myeloid Leukemias
急性髓系白血病的抗代谢药
  • 批准号:
    9909414
  • 财政年份:
    2020
  • 资助金额:
    $ 76.37万
  • 项目类别:
Propargyl-linked Antifolates Targeting Klebsiella pneumoniae
针对肺炎克雷伯菌的炔丙基连接抗叶酸剂
  • 批准号:
    9178633
  • 财政年份:
    2013
  • 资助金额:
    $ 76.37万
  • 项目类别:
Propargyl-linked Antifolates Targeting Klebsiella pneumoniae
针对肺炎克雷伯菌的炔丙基连接抗叶酸剂
  • 批准号:
    8960331
  • 财政年份:
    2013
  • 资助金额:
    $ 76.37万
  • 项目类别:
HDAC Inhibitors Inspired by Natural Products
受天然产物启发的 HDAC 抑制剂
  • 批准号:
    8191877
  • 财政年份:
    2011
  • 资助金额:
    $ 76.37万
  • 项目类别:
HDAC Inhibitors Inspired by Natural Products
受天然产物启发的 HDAC 抑制剂
  • 批准号:
    8293024
  • 财政年份:
    2011
  • 资助金额:
    $ 76.37万
  • 项目类别:
STRATEGIC USE OF FURAN IN THE SYNTHESIS OF MOLECULES OF BIOLOGICAL IMPORTANCE
呋喃在具有生物重要性的分子合成中的战略用途
  • 批准号:
    7721467
  • 财政年份:
    2008
  • 资助金额:
    $ 76.37万
  • 项目类别:

相似海外基金

The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
  • 批准号:
    EP/Z000920/1
  • 财政年份:
    2025
  • 资助金额:
    $ 76.37万
  • 项目类别:
    Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
  • 批准号:
    FT230100276
  • 财政年份:
    2024
  • 资助金额:
    $ 76.37万
  • 项目类别:
    ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
  • 批准号:
    MR/X024261/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.37万
  • 项目类别:
    Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
  • 批准号:
    DE240100388
  • 财政年份:
    2024
  • 资助金额:
    $ 76.37万
  • 项目类别:
    Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
  • 批准号:
    2889694
  • 财政年份:
    2023
  • 资助金额:
    $ 76.37万
  • 项目类别:
    Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
  • 批准号:
    2842926
  • 财政年份:
    2023
  • 资助金额:
    $ 76.37万
  • 项目类别:
    Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
  • 批准号:
    NC/X001644/1
  • 财政年份:
    2023
  • 资助金额:
    $ 76.37万
  • 项目类别:
    Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
  • 批准号:
    2337595
  • 财政年份:
    2023
  • 资助金额:
    $ 76.37万
  • 项目类别:
    Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
  • 批准号:
    2232190
  • 财政年份:
    2023
  • 资助金额:
    $ 76.37万
  • 项目类别:
    Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
  • 批准号:
    23K17514
  • 财政年份:
    2023
  • 资助金额:
    $ 76.37万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了